Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Acute respiratory distress syndrome (ARDS) is associated with high mortality, some of which can be attributed to ventilator-induced lung injury (VILI) when artificial ventilation is not customized to the severity of lung injury. As ARDS is characterized by a decrease in aerated lung volume, reducing tidal volume (VT) from 12 to 6 mL/kg of predicted body weight (PBW) was shown to improve survival more than 20 years ago. Since then, the VT has been normalized to the PBW, meaning to the theoretical lung size (before the disease), rather than tailored to the severity of lung injury, i.e., to the size of aerated lung volume. During ARDS, the aerated lung volume is correlated to the respiratory system compliance (Crs). The driving pressure (ΔP), defined as the difference between the plateau pressure and the positive end expiratory pressure, represents the ratio between the VT and the Crs. Therefore, the ΔP normalizes the VT to a surrogate of the aerated lung available for ventilation of the diseased lung, rather than to the theoretical lung size of the healthy lung, and thus represents more accurately the actual strain applied to the lungs. In a post hoc analysis of 9 randomized controlled trials, Amato et al. found that higher ΔP was a better predictor of mortality than higher VT, with an increased risk of death when the ΔP > 14 cm H2O. These findings have been confirmed in subsequent meta-analysis and large-scale observational data. In a prospective study including 50 patients, the investigators showed that a ΔPguided ventilation strategy targeting a ΔP between 12 and 14 cm H2O significantly reduced the mechanical power, a surrogate for the risk of VILI, compared to a conventional PBW-guided ventilation. In the present study, the investigators hypothesize that the physiological individualization of ventilation (ΔP-guided VT) may improve the outcome of patients with ARDS compared to traditional anthropometrical adjustment (PBW-guided VT)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ΔP-guided VT group | Experimental | During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target |
|
| PBW-guided VT group | Active Comparator | The VT will be kept at 6 mL/kg of PBW. If the plateau pressure threshold is reached (30 cm H2O), the VT will be decreased down to a minimal value of 4 mL/kg of PBW. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tidal volume customization in the acute respiratory distress syndrome | Other | During volume assist control ventilation, the VT will be adjusted in supine position to target a 12 ≤ ΔP ≤ 14 cm H2O. The allowed minimal and maximal values of VT are consistent with usual practices reported in large observational studies 4 and 10 mL/kg of PBW, respectively, while keeping a plateau pressure below 30 cm H2O. The respiratory rate will then be adjusted to meet the pH target |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | The primary endpoint is a ranked composite score that prioritizes 28-day mortality, followed by days free from mechanical ventilation through day 28 for the survivors. Thus, the score is calculated in such a manner that death constitutes a worse outcome than fewer days off the ventilator. | 28 days |
| Number of days free from mechanical ventilation | The primary endpoint is a ranked composite score that prioritizes 28-day mortality, followed by days free from mechanical ventilation through day 28 for the survivors. Thus, the score is calculated in such a manner that death constitutes a worse outcome than fewer days off the ventilator. | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Ventilator parameters | up to Day 7 | |
| Arterial blood gases | Arterial blood gases (pH, PaO2, PaCO2, HCO3-), recorded in supine position between 6:00 and 12:00 a.m. once a day up to day 7 | up to Day 7 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guillaume CARTEAUX, Pr | Contact | +33 (0)1 49 81 43 85 | guillaume.carteaux@aphp.fr |
Not provided
Not provided
DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| D055397 | Ventilator-Induced Lung Injury |
| D000168 | Acrocephalosyndactylia |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D055370 | Lung Injury |
Not provided
Not provided
comparing ΔP-guided VT to traditional PBW-guided VT during mechanical ventilation of patients with ARDS.
Not provided
Not provided
Not provided
Not provided
|
| Mortality | ICU mortality and hospital mortality | Day-28, Day 90 |
| Number of days alive without ventilation | Number of days alive without ventilation between randomization and day 28; | Up to Day 28 |
| Sequential Organ Failure Assessment score (SOFA) | SOFA score | Day 1, Day 3 and Day 7 |
| Number of days alive without catecholamine | Number of days alive without catecholamine between randomization and day 28, assessed as a hierarchical endpoint prioritized on 28-day mortality; | Up to Day 28 |
| Number of days alive without continuous sedation | Number of days alive without continuous sedation between randomization and day 28, assessed as a hierarchical endpoint prioritized on 28-day mortality | Up to Day 28 |
| Number of days alive without neuromuscular blockers | Number of days alive without neuromuscular blockers between randomization and day 28, assessed as a hierarchical endpoint prioritized on 28-day mortality; | UP to Day 28 |
| Number of prone position sessions | Number of prone position sessions | Up to Day 28 |
| Use of rescue procedures: inhaled nitric oxide, almitrine, ECMO, ECCO2R | Use of rescue procedures: inhaled nitric oxide, almitrine, ECMO, ECCO2R | Up to Day 28 |
| Occurrence of ventilator-associated pneumothorax | Occurrence of ventilator-associated pneumothorax between randomization and day 28; | Up to Day 28 |
| Time to pressure support ventilation; | Time between randomization and transition to pressure support ventilation; | Up to Day 28 |
| Duration of weaning unreadiness | Duration of weaning unreadiness measured as the time between randomization and initiation of weaning from mechanical ventilation, defined as the day of the first spontaneous breathing trial; | Up to Day 28 |
| Duration of weaning | Duration of weaning, defined as the time between the first spontaneous breathing trial and successful extubation | Up to day 28 |
| The rate of tracheostomy | The rate of tracheostomy | Up to Day 28 |
| Total duration of mechanical ventilation | Total duration of mechanical ventilation, from intubation to successful extubation, defined as an extubation not followed by reintubation or death within the next 7 days; | up to Day 7 |
| Length of stay | Length of stay in the ICU and in hospital; | up to Day 28 |
| D003398 |
| Craniosynostoses |
| D013580 | Synostosis |
| D004413 | Dysostoses |
| D001848 | Bone Diseases, Developmental |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D013576 | Syndactyly |
| D019465 | Craniofacial Abnormalities |
| D009139 | Musculoskeletal Abnormalities |
| D017880 | Limb Deformities, Congenital |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |